What MEST-C scores predict ESRD progression in IgAN?

M1 (mesangial score >0.5): worse prognosis; E1 (any endocapillary proliferation): worse; S1 (any segmental sclerosis): worse; T1 (tubular atrophy/interstitial fibrosis 26-50%): worst prognosis; T2 (>50%): ESRD within 10 years in majority; C (crescents) adds acute activity score.

What proteinuria target reduces IgAN progression?

Proteinuria target <0.5 g/day (ideally <0.3 g/day) with ACEi/ARB-based BP control <125/75 mmHg; TESTING and STOP-IgAN trial data support targeted proteinuria reduction; sparsentan achieves greater proteinuria reduction than irbesartan.

What is the evidence for budesonide in IgAN?

Targeted release budesonide (Nefecon/Tarpeyo) reduces IgA immune complex formation at gut-associated lymphoid tissue; NEFIGAN trial: 30-45% proteinuria reduction; approved for IgAN with proteinuria >1 g/day and eGFR >35 mL/min.

When should kidney biopsy be performed in IgAN?

Biopsy indicated for: proteinuria >1 g/day, unexplained hematuria + proteinuria, declining GFR; Oxford MEST-C classification guides immunosuppression decision; biopsy essential for Henoch-Schönlein nephritis classification.

What complement pathway is targeted in emerging IgAN therapies?

Complement pathway activation (MASP-2, alternative pathway, C3) drives IgAN inflammation; iptacopan (factor B inhibitor), cemdisiran (C3 siRNA), and MASP-2 antibodies are in trials; target the lectin complement pathway activated by galactose-deficient IgA1.

IgA Nephropathy Oxford MEST-C Score and Progression Risk

Calculates the Oxford MEST-C pathological classification (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental glomerulosclerosis, Tubular atrophy, Crescents) for IgA nephropathy prognosis and sparsentan/budesonide eligibility.

Use the full interactive calculator below, or

Related Calculators

UCD Ammonia Crisis

Medical Calculators

Lupus Nephritis Score

Medical Calculators

DAS28-CRP

Medical Calculators

IgA Nephropathy Oxford MEST-C Score and Progression Risk

Related Calculators

Frequently Asked Questions

What MEST-C scores predict ESRD progression in IgAN?

What proteinuria target reduces IgAN progression?

What is the evidence for budesonide in IgAN?

When should kidney biopsy be performed in IgAN?

What complement pathway is targeted in emerging IgAN therapies?